Have any thoughts about
Seagen Inc?
Write Note

EV/EBIT
Enterprise Value to EBIT

-55.1
Current
-51.6
Median
4.3
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-55.1
=
Enterprise Value
38.2B EUR
/
EBIT
-750.5m USD
All Countries
Close
EBIT Growth
US
S
Seagen Inc
F:SGT
Average EV/EBIT: 72.6
Negative Multiple: -55.1
N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
35.3
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
29.4
44%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
24.7
54%
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -520.1 N/A
AU
CSL Ltd
ASX:CSL
28
55%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
354.4
N/A
KY
Beigene Ltd
SSE:688235
Negative Multiple: -35.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -73.8 N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-49.3
2-Years Forward
EV/EBIT
-97
3-Years Forward
EV/EBIT
358.5

See Also

Discover More